CDK4 and metastatic neoplasm: Patients with HR + metastatic disease had a median of 1 prior line of endocrine therapy (ET) for metastatic disease (IQR 0 − 2), with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in combination with ET (44.6%) being the most common therapy (Tables S1 and S2).